| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 43 | 2025 | 509 | 10.520 |
Why?
|
| Buprenorphine | 22 | 2025 | 193 | 7.960 |
Why?
|
| Substance-Related Disorders | 43 | 2023 | 735 | 7.010 |
Why?
|
| Opiate Substitution Treatment | 32 | 2025 | 207 | 5.650 |
Why?
|
| Substance Abuse Treatment Centers | 28 | 2020 | 104 | 4.050 |
Why?
|
| Methadone | 20 | 2025 | 134 | 3.070 |
Why?
|
| Analgesics, Opioid | 19 | 2025 | 536 | 2.950 |
Why?
|
| Drug Overdose | 7 | 2024 | 131 | 2.610 |
Why?
|
| Prisoners | 9 | 2025 | 165 | 2.420 |
Why?
|
| Crime | 12 | 2017 | 57 | 2.400 |
Why?
|
| Adult | 79 | 2025 | 16896 | 1.860 |
Why?
|
| Allostasis | 2 | 2025 | 10 | 1.790 |
Why?
|
| California | 30 | 2019 | 174 | 1.670 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 6 | 2021 | 26 | 1.580 |
Why?
|
| Qualitative Research | 11 | 2024 | 705 | 1.550 |
Why?
|
| Humans | 122 | 2025 | 63535 | 1.550 |
Why?
|
| Narcotic Antagonists | 8 | 2025 | 137 | 1.470 |
Why?
|
| Female | 86 | 2025 | 32947 | 1.420 |
Why?
|
| Male | 80 | 2025 | 29938 | 1.370 |
Why?
|
| Adult Survivors of Child Adverse Events | 2 | 2019 | 9 | 1.180 |
Why?
|
| Health Services Accessibility | 7 | 2023 | 566 | 1.180 |
Why?
|
| Massachusetts | 12 | 2025 | 2074 | 1.140 |
Why?
|
| Young Adult | 28 | 2024 | 4713 | 1.120 |
Why?
|
| Criminal Law | 4 | 2023 | 82 | 1.110 |
Why?
|
| Naltrexone | 6 | 2025 | 89 | 1.090 |
Why?
|
| Sex Factors | 13 | 2025 | 973 | 1.090 |
Why?
|
| Veterans | 4 | 2022 | 763 | 1.070 |
Why?
|
| Health Status Disparities | 3 | 2017 | 143 | 1.050 |
Why?
|
| Veterans Health | 2 | 2018 | 157 | 1.020 |
Why?
|
| Alcoholism | 5 | 2017 | 317 | 0.990 |
Why?
|
| Middle Aged | 42 | 2024 | 17659 | 0.960 |
Why?
|
| Public Health | 3 | 2023 | 186 | 0.910 |
Why?
|
| Mental Health Services | 7 | 2023 | 288 | 0.860 |
Why?
|
| Mental Recall | 1 | 2024 | 93 | 0.850 |
Why?
|
| Prisons | 8 | 2024 | 111 | 0.850 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 115 | 0.840 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 1259 | 0.820 |
Why?
|
| Community Health Services | 2 | 2018 | 128 | 0.810 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 88 | 0.810 |
Why?
|
| Narcotics | 6 | 2017 | 58 | 0.810 |
Why?
|
| Community Mental Health Services | 6 | 2014 | 94 | 0.810 |
Why?
|
| Cannabis | 2 | 2021 | 51 | 0.800 |
Why?
|
| Butterflies | 4 | 2024 | 34 | 0.790 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2017 | 12 | 0.780 |
Why?
|
| Criminals | 3 | 2013 | 60 | 0.770 |
Why?
|
| Psoriasis | 2 | 2020 | 57 | 0.770 |
Why?
|
| United States | 17 | 2024 | 7837 | 0.750 |
Why?
|
| Adolescent | 25 | 2024 | 6258 | 0.710 |
Why?
|
| Recidivism | 1 | 2022 | 30 | 0.710 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 2464 | 0.700 |
Why?
|
| Health Personnel | 4 | 2022 | 377 | 0.690 |
Why?
|
| Stress, Psychological | 1 | 2025 | 474 | 0.670 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 844 | 0.660 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 363 | 0.640 |
Why?
|
| Caregivers | 2 | 2020 | 277 | 0.640 |
Why?
|
| Prediabetic State | 1 | 2020 | 53 | 0.630 |
Why?
|
| Conduct Disorder | 1 | 2019 | 24 | 0.620 |
Why?
|
| Patients | 1 | 2020 | 113 | 0.620 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 541 | 0.600 |
Why?
|
| Anxiety Disorders | 2 | 2019 | 192 | 0.570 |
Why?
|
| Cocaine-Related Disorders | 5 | 2017 | 82 | 0.570 |
Why?
|
| Treatment Outcome | 25 | 2024 | 5630 | 0.570 |
Why?
|
| Musculoskeletal Pain | 1 | 2018 | 28 | 0.570 |
Why?
|
| Methamphetamine | 6 | 2017 | 26 | 0.570 |
Why?
|
| Complementary Therapies | 1 | 2018 | 62 | 0.550 |
Why?
|
| Law Enforcement | 4 | 2017 | 26 | 0.530 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 37 | 0.510 |
Why?
|
| Life Change Events | 1 | 2017 | 66 | 0.510 |
Why?
|
| Dementia | 2 | 2016 | 262 | 0.500 |
Why?
|
| Personal Autonomy | 1 | 2016 | 70 | 0.490 |
Why?
|
| Medicaid | 1 | 2020 | 361 | 0.480 |
Why?
|
| Chronic Pain | 1 | 2018 | 154 | 0.480 |
Why?
|
| Aged | 15 | 2024 | 14457 | 0.480 |
Why?
|
| Health Services Needs and Demand | 3 | 2016 | 211 | 0.460 |
Why?
|
| Mothers | 5 | 2014 | 276 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 485 | 0.450 |
Why?
|
| Homes for the Aged | 1 | 2016 | 161 | 0.450 |
Why?
|
| Program Evaluation | 7 | 2025 | 487 | 0.440 |
Why?
|
| Mental Health | 1 | 2018 | 371 | 0.440 |
Why?
|
| Heroin Dependence | 3 | 2017 | 22 | 0.430 |
Why?
|
| Patient Safety | 1 | 2016 | 243 | 0.420 |
Why?
|
| Pandemics | 4 | 2022 | 671 | 0.420 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2019 | 119 | 0.420 |
Why?
|
| Social Environment | 1 | 2014 | 93 | 0.410 |
Why?
|
| Safety | 1 | 2014 | 145 | 0.410 |
Why?
|
| Patient Dropouts | 3 | 2011 | 49 | 0.400 |
Why?
|
| Perception | 1 | 2014 | 175 | 0.400 |
Why?
|
| Aphasia | 2 | 2024 | 45 | 0.400 |
Why?
|
| Gender Identity | 3 | 2023 | 68 | 0.390 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2016 | 78 | 0.390 |
Why?
|
| Residence Characteristics | 1 | 2014 | 219 | 0.390 |
Why?
|
| Policy | 2 | 2021 | 56 | 0.370 |
Why?
|
| Mental Disorders | 3 | 2015 | 794 | 0.360 |
Why?
|
| Employment | 2 | 2009 | 128 | 0.350 |
Why?
|
| Prevalence | 3 | 2020 | 1386 | 0.340 |
Why?
|
| Nursing Homes | 1 | 2016 | 671 | 0.330 |
Why?
|
| Recurrence | 6 | 2012 | 641 | 0.330 |
Why?
|
| Cohort Studies | 10 | 2024 | 2572 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2019 | 3296 | 0.310 |
Why?
|
| Patient Compliance | 5 | 2012 | 360 | 0.310 |
Why?
|
| Mandatory Programs | 1 | 2008 | 18 | 0.300 |
Why?
|
| Drug Users | 1 | 2008 | 28 | 0.290 |
Why?
|
| Databases as Topic | 1 | 2008 | 51 | 0.280 |
Why?
|
| Interviews as Topic | 4 | 2024 | 531 | 0.270 |
Why?
|
| Skin | 3 | 2020 | 374 | 0.270 |
Why?
|
| Referral and Consultation | 1 | 2011 | 427 | 0.270 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2584 | 0.270 |
Why?
|
| Data Collection | 2 | 2006 | 384 | 0.270 |
Why?
|
| Age Factors | 6 | 2016 | 1561 | 0.260 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.260 |
Why?
|
| Sex Distribution | 2 | 2017 | 252 | 0.260 |
Why?
|
| Secondary Prevention | 4 | 2013 | 164 | 0.250 |
Why?
|
| Schizophrenia | 2 | 2022 | 263 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 784 | 0.250 |
Why?
|
| Comorbidity | 3 | 2021 | 1115 | 0.250 |
Why?
|
| Drug and Narcotic Control | 4 | 2007 | 28 | 0.240 |
Why?
|
| HIV Infections | 5 | 2016 | 972 | 0.240 |
Why?
|
| Indians, North American | 1 | 2006 | 29 | 0.240 |
Why?
|
| Depression | 2 | 2021 | 908 | 0.240 |
Why?
|
| Time Factors | 8 | 2018 | 3710 | 0.230 |
Why?
|
| Research Design | 1 | 2008 | 575 | 0.230 |
Why?
|
| Wings, Animal | 1 | 2024 | 20 | 0.220 |
Why?
|
| Pigmentation | 1 | 2024 | 24 | 0.220 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2015 | 87 | 0.220 |
Why?
|
| Poetry as Topic | 1 | 2004 | 3 | 0.220 |
Why?
|
| Age of Onset | 3 | 2017 | 174 | 0.210 |
Why?
|
| Incidence | 2 | 2025 | 1374 | 0.210 |
Why?
|
| Income | 1 | 2024 | 170 | 0.200 |
Why?
|
| Privacy | 1 | 2023 | 13 | 0.200 |
Why?
|
| Intellectual Disability | 2 | 2016 | 168 | 0.200 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 223 | 0.200 |
Why?
|
| Social Stigma | 1 | 2023 | 73 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 2 | 2017 | 64 | 0.190 |
Why?
|
| Inflammation | 2 | 2020 | 1146 | 0.190 |
Why?
|
| Grounded Theory | 1 | 2022 | 19 | 0.190 |
Why?
|
| Health Services Research | 2 | 2023 | 270 | 0.190 |
Why?
|
| Risk Factors | 4 | 2018 | 5284 | 0.190 |
Why?
|
| Prescription Drug Diversion | 1 | 2022 | 7 | 0.190 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 435 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 170 | 0.190 |
Why?
|
| Inpatients | 2 | 2021 | 304 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 346 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 205 | 0.180 |
Why?
|
| Mood Disorders | 2 | 2019 | 72 | 0.180 |
Why?
|
| Anxiety | 2 | 2022 | 429 | 0.170 |
Why?
|
| Adaptation, Psychological | 3 | 2016 | 267 | 0.170 |
Why?
|
| Acute Pain | 1 | 2021 | 21 | 0.170 |
Why?
|
| Quality of Life | 3 | 2022 | 1241 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 17 | 0.170 |
Why?
|
| Data Anonymization | 1 | 2020 | 1 | 0.170 |
Why?
|
| Terminal Care | 1 | 2022 | 110 | 0.170 |
Why?
|
| Feeding and Eating Disorders | 1 | 2021 | 49 | 0.170 |
Why?
|
| Neoplasms | 2 | 2024 | 1373 | 0.170 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2704 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 28 | 0.160 |
Why?
|
| Risk-Taking | 3 | 2016 | 162 | 0.160 |
Why?
|
| Social Media | 1 | 2022 | 125 | 0.160 |
Why?
|
| Personality Disorders | 1 | 2019 | 20 | 0.160 |
Why?
|
| Focus Groups | 3 | 2016 | 305 | 0.160 |
Why?
|
| Health Equity | 1 | 2020 | 46 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2020 | 69 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 54 | 0.150 |
Why?
|
| Autistic Disorder | 1 | 2021 | 146 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 248 | 0.150 |
Why?
|
| Sensory Receptor Cells | 1 | 2018 | 19 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 332 | 0.150 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 280 | 0.140 |
Why?
|
| Stroke | 2 | 2024 | 1184 | 0.140 |
Why?
|
| Child | 8 | 2024 | 4541 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 312 | 0.130 |
Why?
|
| Logistic Models | 3 | 2017 | 1267 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 49 | 0.130 |
Why?
|
| Financing, Government | 1 | 2017 | 31 | 0.130 |
Why?
|
| England | 1 | 2016 | 30 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 604 | 0.130 |
Why?
|
| Behavioral Symptoms | 1 | 2016 | 14 | 0.130 |
Why?
|
| Risk Management | 1 | 2016 | 39 | 0.120 |
Why?
|
| Insulin | 1 | 2020 | 686 | 0.120 |
Why?
|
| Siblings | 1 | 2016 | 43 | 0.120 |
Why?
|
| Motivation | 2 | 2009 | 287 | 0.120 |
Why?
|
| Animals | 7 | 2024 | 20716 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 158 | 0.120 |
Why?
|
| Diquat | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2020 | 988 | 0.120 |
Why?
|
| Paraquat | 1 | 2016 | 14 | 0.120 |
Why?
|
| Environment | 1 | 2016 | 123 | 0.120 |
Why?
|
| Herbicides | 1 | 2016 | 19 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2196 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3402 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 220 | 0.120 |
Why?
|
| Telemedicine | 1 | 2020 | 330 | 0.120 |
Why?
|
| Health Surveys | 1 | 2017 | 313 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 32 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1553 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 94 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 102 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2016 | 149 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2017 | 295 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2017 | 256 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 398 | 0.110 |
Why?
|
| Self Report | 2 | 2021 | 381 | 0.110 |
Why?
|
| Olfactory Perception | 1 | 2014 | 3 | 0.110 |
Why?
|
| Population Density | 1 | 2014 | 14 | 0.110 |
Why?
|
| Glucose | 1 | 2017 | 468 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 44 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 541 | 0.110 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 15 | 0.110 |
Why?
|
| Smell | 1 | 2014 | 28 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 16 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2014 | 48 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2016 | 218 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2025 | 1015 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 168 | 0.100 |
Why?
|
| Pain Management | 1 | 2016 | 163 | 0.100 |
Why?
|
| Health Status | 1 | 2016 | 443 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 226 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 162 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 699 | 0.100 |
Why?
|
| Climacteric | 1 | 2012 | 4 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 158 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 301 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2012 | 79 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 136 | 0.090 |
Why?
|
| Parents | 1 | 2016 | 393 | 0.090 |
Why?
|
| Tobacco Use Cessation | 1 | 2012 | 29 | 0.090 |
Why?
|
| Disease Progression | 1 | 2016 | 1170 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 762 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 313 | 0.090 |
Why?
|
| Rehabilitation Centers | 1 | 2011 | 12 | 0.090 |
Why?
|
| Aging | 2 | 2015 | 745 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2024 | 1999 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6620 | 0.080 |
Why?
|
| Health Care Surveys | 2 | 2008 | 285 | 0.080 |
Why?
|
| Phenotype | 2 | 2024 | 1208 | 0.080 |
Why?
|
| Genomics | 2 | 2023 | 375 | 0.080 |
Why?
|
| Mice | 2 | 2020 | 10864 | 0.080 |
Why?
|
| Infant | 3 | 2021 | 1654 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Utilization Review | 1 | 2008 | 32 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 863 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 378 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 5468 | 0.060 |
Why?
|
| Exercise | 1 | 2014 | 946 | 0.060 |
Why?
|
| Public Health Administration | 1 | 2006 | 22 | 0.060 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 146 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2025 | 2027 | 0.060 |
Why?
|
| Ethics, Clinical | 1 | 2006 | 3 | 0.060 |
Why?
|
| Forensic Psychiatry | 1 | 2006 | 68 | 0.060 |
Why?
|
| Confidentiality | 1 | 2006 | 56 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 436 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 40 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2004 | 42 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2024 | 33 | 0.050 |
Why?
|
| Genome Size | 1 | 2023 | 1 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2024 | 58 | 0.050 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 2 | 0.050 |
Why?
|
| Marijuana Abuse | 2 | 2017 | 21 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2025 | 728 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2024 | 127 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2024 | 81 | 0.050 |
Why?
|
| Psycholinguistics | 1 | 2023 | 36 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2023 | 56 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 138 | 0.050 |
Why?
|
| Reproductive Isolation | 1 | 2022 | 5 | 0.050 |
Why?
|
| Genetic Speciation | 1 | 2022 | 6 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 230 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2022 | 19 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 197 | 0.050 |
Why?
|
| Language | 1 | 2024 | 150 | 0.050 |
Why?
|
| Neon | 1 | 2022 | 1 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 378 | 0.050 |
Why?
|
| Death | 1 | 2022 | 31 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 237 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2023 | 167 | 0.050 |
Why?
|
| Muscarinic Antagonists | 1 | 2022 | 33 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2022 | 122 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 137 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2022 | 140 | 0.040 |
Why?
|
| State Government | 1 | 2021 | 32 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 60 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 366 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 807 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2020 | 39 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 67 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2022 | 322 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 345 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 82 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 151 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 843 | 0.040 |
Why?
|
| Drosophila | 1 | 2022 | 435 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 484 | 0.040 |
Why?
|
| Hypertension | 1 | 2024 | 590 | 0.040 |
Why?
|
| TRPA1 Cation Channel | 1 | 2018 | 3 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2018 | 8 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2018 | 11 | 0.040 |
Why?
|
| Substance P | 1 | 2018 | 38 | 0.040 |
Why?
|
| Diterpenes | 1 | 2018 | 21 | 0.040 |
Why?
|
| Denervation | 1 | 2018 | 19 | 0.040 |
Why?
|
| TRPV Cation Channels | 1 | 2018 | 20 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.040 |
Why?
|
| Hospitalization | 1 | 2025 | 1360 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 607 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 64 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 225 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2011 | 606 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 208 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 222 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 90 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2016 | 60 | 0.030 |
Why?
|
| Crime Victims | 1 | 2017 | 35 | 0.030 |
Why?
|
| Accidents, Occupational | 1 | 2016 | 44 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 199 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 194 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 61 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 369 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2015 | 104 | 0.030 |
Why?
|
| Seizures | 1 | 2015 | 143 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 2335 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 2015 | 132 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 372 | 0.030 |
Why?
|
| Pediatrics | 1 | 2016 | 257 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2016 | 315 | 0.020 |
Why?
|
| British Columbia | 1 | 2012 | 5 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 105 | 0.020 |
Why?
|
| New York | 1 | 2012 | 143 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 299 | 0.020 |
Why?
|
| Prescription Drug Misuse | 1 | 2011 | 21 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 174 | 0.020 |
Why?
|
| China | 1 | 2011 | 165 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Reward | 1 | 2011 | 87 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 160 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 866 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 390 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2008 | 27 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 70 | 0.020 |
Why?
|
| Substance Abuse Detection | 1 | 2007 | 45 | 0.020 |
Why?
|
| Episode of Care | 1 | 2006 | 8 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2006 | 96 | 0.010 |
Why?
|
| Patient Admission | 1 | 2006 | 198 | 0.010 |
Why?
|
| Residential Treatment | 1 | 2004 | 34 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2004 | 311 | 0.010 |
Why?
|